Opioid, cannabinoid, cocaine, and methamphetamine epidemics: History, risk factors associated with them, and characteristics of drug action

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the last century, mankind has made significant progress in the search and study of new pain-relieving drugs through the targeted synthesis of chemical analogs of natural opioids, cannabinoids, cocaine, and amphetamines. Experience with the medical use of new synthetic opioids, cannabinoids, and amphetamines has shown not only their high analgesic efficacy but also their high danger because of the risks of drug dependence and addiction, which have caused drug epidemics. The paper described the history of relevant drug epidemics, and the pharmacodynamics and pharmacokinetics of the most dangerous drugs, as well as the risks associated with drug epidemics, were outlined. Specifically, the risk of drug dependence to opioids, cannabinoids, amphetamine, and cocaine was not recognized until too late. Therefore, the drug crisis was initially largely iatrogenic. In recent decades, controls on the prescription of narcotic drugs have tightened; thus, drug addiction as iatrogeny occurs less frequently. However, criminal elements of society have established clandestine production of drugs and their realization in the youth and LGBT community disguising as new, fashionable designer drugs and devices for their use. Moreover, new synthetic drugs differ from natural drugs in their stronger psychostimulant effects, ability to cause addiction after the first use, and high risk of fatal poisoning. Thus far, no drugs were the treatment of opioid, cannabinoid, amphetamine, and cocaine abuse. However, the development of specific vaccines for these drugs has begun in recent years. Active immunization of drug abusers with specially created vaccines is expected to assist doctors in treating drug abusers in the future.

Full Text

Restricted Access

About the authors

Aleksandr L. Urakov

Izhevsk State Medical Academy

Author for correspondence.
Email: urakoval@live.ru
ORCID iD: 0000-0002-9829-9463
SPIN-code: 1613-9660

Dr. Sci. (Med., Pharmacology), professor, head of Pharmacology and Clinical Pharmacology Department

Russian Federation, 281, Kommunarov str., Izhevsk, 426034

Petr D. Shabanov

Institute of Experimental Medicine

Email: pdshabanov@mail.ru
ORCID iD: 0000-0003-1464-1127
SPIN-code: 8974-7477

Dr. Sci. (Med., Pharmacology), professor

Russian Federation, Saint Petersburg

References

  1. Hamilton GR, Baskett TF. In the arms of Morpheus the development of morphine for postoperative pain relief. Can J Anaesth. 2000;47(4):367–374. DOI: 10. 1007/BF03020955
  2. Reisner L. Biologic poisons for pain. Curr Pain Headache Rep. 2004;8(6):427–434. DOI: 10. 1007/s11916-004-0063-3
  3. Norn S, Kruse PR, Kruse E. History of opium poppy and morphine. Dan Medicinhist Arbog. 2005;33:171–184. (In Danish)
  4. Klockgether-Radke AP. F. W. Sertürner and the discovery of morphine. 200 years of pain therapy with opioids. Anasthesiol Intensivmed Notfallmed Schmerzther. 2002;37(5):244–249. (In German). DOI: 10. 1055/S-2002-30132
  5. Brook K, Bennett J, Desai SP. The chemical history of morphine: An 8000-year journey, from resin to de-novo synthesis. J Anesth Hist. 2017;3(2):50–55. DOI: 10. 1016/j. janh. 2017. 02. 001
  6. Listos J, Łupina M, Talarek S, et al. The mechanisms involved in morphine addiction: An overview. Int J Mol Sci. 2019;20(17):4302. DOI: 10. 3390/ijms20174302
  7. Robert M, Jouanjus E, Khouri C, et al. The opioid epidemic: A worldwide exploratory study using the WHO pharmacovigilance database. Addiction. 2023;118(4):771–775. DOI: 10. 1111/add. 16081
  8. Musto DF. Cocaine’s history, especially the American experience. Ciba Found Symp 166: Cocaine: Scientific and Social Dimensions. 1992. P. 7–19. DOI: 10. 1002/9780470514245. ch2
  9. Musto DF. Opium, cocaine and marijuana in American history. Sci Am. 1991;265(1):40–47. DOI: 10. 1038/scientificamerican0791-40
  10. Crocq M-A. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223–228. DOI: 10. 31887/DCNS. 2020. 22. 3/mcrocq
  11. Charitos IA, Gagliano-Candela R, Santacroce L, Bottalico L. The cannabis spread throughout the continents and its therapeutic use in history. Endocr Metab Immune Disord Drug Targets. 2021;21(3):407–417. DOI: 10. 2174/1871530320666200520095900
  12. Phillips J, Lim F, Hsu R. The emerging threat of synthetic cannabinoids. Nurs Manage. 2017;48(3):22–30. DOI: 10. 1097/01. NUMA. 0000512504. 16830. b6
  13. Rasmussen N. America’s first amphetamine epidemic 1929–1971: a quantitative and qualitative retrospective with implications for the present. Am J Public Health. 2008;98(6):974–985. DOI: 10. 2105/AJPH. 2007. 110593
  14. Moore TJ, Wirtz PW, Curran JN, Alexander GC. Medical use and combination drug therapy among US adult users of central nervous system stimulants: a cross-sectional analysis. BMJ Open. 2023;13(4):e069668. DOI: 10. 1136/bmjopen-2022-069668
  15. Maxwell JC, Brecht M-L. Methamphetamine: here we go again? Addict Behav. 2011;36(12):1168–1173. DOI: 10. 1016/j. addbeh. 2011. 07. 017
  16. LaBossier NJ, Hadland SE. Stimulant misuse among youth. Curr Probl Pediatr Adolesc Health Care. 2022;52(9):101265. DOI: 10. 1016/j. cppeds. 2022. 101265
  17. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006;26(8):1148–1156. DOI: 10. 1592/phco. 26. 8. 1148
  18. Westover AN, Nakonezny PA, Halm EA, Adinoff B. Risk of amphetamine use disorder and mortality among incident users of prescribed stimulant medications in the Veterans Administration. Addiction. 2018;113(5):857–867. DOI: 10. 1111/add. 14122
  19. Shafi A, Berry AJ, Sumnall H, et al. Synthetic opioids: a review and clinical update. Ther Adv Psychopharmacol. 2022;12:20451253221139616. DOI: 10. 1177/20451253221139616
  20. Raheemullah A, Andruska N. Fentanyl analogue overdose: Key lessons in management in the synthetic opioid age. J Opioid Manag. 2019;15(5):428–432. DOI: 10. 5055/jom. 2019. 0531
  21. Cibulsky SM, Wille T, Funk R, et al. Public health and medical preparedness for mass casualties from the deliberate release of synthetic opioids. Front Public Health. 2023;11:1158479. DOI: 10. 3389/fpubh. 2023. 1158479
  22. Zawilska JB. An expanding world of novel psychoactive substances: Opioids. Front Psychiatry. 2017;8:110. DOI: 10. 3389/fpsyt. 2017. 00110
  23. Preuss CV, Kalava A, King KC. Prescription of controlled substances: Benefits and risks. StatPearls. Treasure Island (FL): StatPearls Publishing, 2023.
  24. Horn DB, Vu L, Porter BR, Sarantopoulos K. Responsible controlled substance and opioid prescribing. StatPearls. Treasure Island (FL): StatPearls Publishing, 2023.
  25. Dydyk AM, Sizemore DC, Fariba KA, et al. Florida сontrolled substance prescribing. StatPearls. Treasure Island (FL): StatPearls Publishing, 2022.
  26. Upp LA, Waljee JF. The opioid epidemic. Clin Plast Surg. 2020;47(2):181–190. DOI: 10. 1016/j. cps. 2019. 12. 005
  27. Harbaugh CM, Gadepalli SK. Pediatric postoperative opioid prescribing and the opioid crisis. Curr Opin Pediatr. 2019;31(3):378–385. DOI: 10. 1097/MOP. 0000000000000768
  28. Goldberg RF. The opioid crisis: The surgeon’s role. Adv Surg. 2019;53:305–325. DOI: 10. 1016/j. yasu. 2019. 04. 015
  29. Chisholm-Burns MA, Spivey CA, Sherwin E, et al. The opioid crisis: Origins, trends, policies, and the roles of pharmacists. Am J Health Syst Pharm. 2019;76(7):424–435. DOI: 10. 1093/ajhp/zxy089
  30. Bowlby MA, Crawford ME. Opioid crisis and acute pain management after foot and ankle surgery. Clin Podiatr Med Surg. 2019;36(4):695–705. DOI: 10. 1016/j. cpm. 2019. 06. 009
  31. Pérez-Mañá C, Papaseit E, Fonseca F, et al. Drug interactions with new synthetic opioids. Front Pharmacol. 2018;9:1145. DOI: 10. 3389/fphar. 2018. 01145
  32. Baumann MH, Majumdar S, Le Rouzic V, et al. Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology. 2018;134(Pt. A):101–107. DOI: 10. 1016/j. neuropharm. 2017. 08. 016
  33. Vandeputte MM, Tsai MM, Chen L, et al. Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide. Drug Alcohol Depend. 2023;249:109939. DOI: 10. 1016/j. drugalcdep. 2023. 109939
  34. Rojek S, Poljańska E, Chaim W, et al. Metabolic evaluation of synthetic opioids on the example of U-47700 with the use of in vitro and in vivo methods for forensic toxicology application. Toxics. 2023;11(3):220. DOI: 10. 3390/toxics11030220
  35. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett. 2004;25(1-2):14–23.
  36. Schlienz NJ, Lee DC. Co-use of cannabis, tobacco, and alcohol during adolescence: policy and regulatory implications. Int Rev Psychiatry. 2018;30(3):226–237. DOI: 10. 1080/09540261. 2018. 1465399
  37. Padon AA, Young-Wolff KC, Avalos LA, Silver LD. Local laws regulating cannabis in California two years post legalization: Assessing incorporation of lessons from tobacco control. Cannabis. 2022;5(3):47–60. DOI: 10. 26828/cannabis/2022. 03. 005
  38. Urakov AL. Synthetic and natural cannabinoids, grass wild hemp (marijuana, cannabis), hashish, spice, «aroma mix», managa: pharmacological effects of smoking and ingestion. Advances in current natural sciences. 2014;(2):21–26. (In Russ. )
  39. Dube SR, Pathak S, Nyman AL, Eriksen MP. Electronic cigarette and electronic hookah: A pilot study comparing two vaping products. Prev Med Rep. 2015;2:953–958. DOI: 10. 1016/j. pmedr. 2015. 10. 012
  40. Wagoner KG, Cornacchione J, Wiseman KD, et al. E-cigarettes, hookah pens and vapes: Adolescent and young adult perceptions of electronic nicotine delivery systems. Nicotine Tob Res. 2016;18(10):2006–2012. DOI: 10. 1093/ntr/ntw095
  41. Rezk-Hanna M, Gupta R, Nettle CO, et al. Differential effects of electronic hookah vaping and traditional combustible hookah smoking on oxidation, inflammation, and arterial stiffness. Chest. 2022;161(1):208–218. DOI: 10. 1016/j. chest. 2021. 07. 027
  42. Rodriguez-Almaraz JE, Butowski N. Therapeutic and supportive effects of cannabinoids in patients with brain tumors (CBD oil and cannabis). Curr Treat Options Oncol. 2023;24:30–44. DOI: 10. 1007/s11864-022-01047-y
  43. Stampanoni Bassi M, Gilio L, Maffei P, et al. Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression. Front Mol Neurosci. 2018;11:424. DOI: 10. 3389/fnmol. 2018. 00424
  44. Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41. DOI: 10. 1016/j. drugalcdep. 2014. 08. 005
  45. Henshaw FR, Dewsbury LS, Lim CK, Steiner GZ. The effects of cannabinoids on pro- and anti-inflammatory cytokines: A systematic review of in vivo studies. Cannabis Cannabinoid Res. 2021;6(3):177–195. DOI: 10. 1089/can. 2020. 0105
  46. Gudsoorkar VS, Perez JA Jr. A new differential diagnosis: Synthetic cannabinoids-associated acute renal failure. Methodist Debakey Cardiovasc J. 2015;11(3):189–191. DOI: 10. 14797/mdcj-11-3-189
  47. de Oliveira MC, Vides MC, Lassi DLS, et al. Toxicity of synthetic cannabinoids in K2/Spice: A systematic review. Brain Sci. 2023;13(7):990. DOI: 10. 3390/brainsci13070990
  48. Izquierdo-Luengo C, Ten-Blanco M, Ponce-Renilla M, et al. Adolescent exposure to the Spice/K2 cannabinoid JWH-018 impairs sensorimotor gating and alters cortical perineuronal nets in a sex-dependent manner. Transl Psychiatry. 2023;13(1):176. DOI: 10. 1038/s41398-023-02469-4
  49. Vosburg SK, Robbins RS, Antshel KM, et al. Characterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit. Addict Behav Rep. 2021;14:100376. DOI: 10. 1016/j. abrep. 2021. 100376
  50. Urakov AL. Amphetamines: quality, methods of production, composition, pharmacological effects. Problemy ehkspertizy v meditsine. 2014;(1):50–52. (In Russ. )
  51. Shabanov PD. Narkologiya. Prakticheskoe rukovodstvo dlya vrachei. Moscow: GEOTAR-MED, 2003. 660 p. (In Russ. )
  52. Weisheit R, White WL. Methamphetamine: Its history, pharmacology and treatment. Hazelden, 2009. 296 p.
  53. Shabanov PD, Shtakel’berg OYu. Narkomanii: Patopsikhologiya, klinika, reabilitatsiya. Seriya: Mir meditsiny. Saint Petersburg: Lan’, 2000. 367 p. (In Russ. )
  54. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101(10):1473–1478. DOI: 10. 1111/j. 1360-0443. 2006. 01496. x
  55. Shabanov PD. Osnovy narkologii. Saint Petersburg: Lan’, 2002. 560 p. (In Russ. )
  56. Zhan S, Ye H, Li N, et al. Comparative efficacy and safety of multiple wake-promoting agents for the treatment of excessive daytime sleepiness in narcolepsy: A network meta-analysis. Nat Sci Sleep. 2023;15:217–230. DOI: 10. 2147/NSS. S404113
  57. Sarker A, Al-Garadi MA, Ge Y, et al. Signals of increasing co-use of stimulants and opioids from online drug forum data. Harm Reduct J. 2022;19(1):51. DOI: 10. 1186/s12954-022-00628-2
  58. Reback CJ, Fletcher JB, Mata RP. A theory-based mHealth intervention (Getting Off) for methamphetamine-using men who have sex with men: Protocol for a randomized controlled trial. JMIR Res Protoc. 2021;10(2):e22572. DOI: 10. 2196/22572
  59. Cheng B, Sang JM, Cui Z, et al. Factors associated with cessation or reduction of methamphetamine use among gay, bisexual, and other men who have sex with men (gbMSM) in vancouver Canada. Subst Use Misuse. 2020;55(10):1692–1701. DOI: 10. 1080/10826084. 2020. 1756854
  60. Khan SI, Khan MNM, Irfan SD, et al. The effects of methamphetamine use on the sexual lives of gender and sexually diverse people in Dhaka, Bangladesh: A qualitative study. Arch Sex Behav. 2021;50(2):479–493. DOI: 10. 1007/s10508-020-01674-2
  61. Card K, McGuire M, Bond-Gorr J, et al. Perceived difficulty of getting help to reduce or abstain from substances among sexual and gender minority men who have sex with men (SGMSM) and use methamphetamine during the early period of the COVID-19 pandemic. Subst Abuse Treat Prev Policy. 2021;16(1):88. DOI: 10. 1186/s13011-021-00425-3
  62. Colyer SP, Moore DM, Cui Z, et al. Crystal methamphetamine use and initiation among gay, bisexual, and other men who have sex with men living with HIV in a treatment as prevention environment. Subst Use Misuse. 2020;55(14):2428–2437. DOI: 10. 1080/10826084. 2020. 1833925
  63. Colyer SP, Lachowsky NJ, Cui Z, et al. HIV treatment optimism and crystal methamphetamine use and initiation among HIV-negative men who have sex with men in Vancouver, Canada: A longitudinal analysis. Drug Alcohol Depend. 2018;185:67–74. DOI: 10. 1016/j. drugalcdep. 2017. 12. 004
  64. Prasad S, Mathew PS, Piper BJ, et al. The neurobiology of methamphetamine addiction and the potential to reduce misuse through conjugate vaccines targeting toll-like receptor 4. Cureus. 2023;15(6):e40259. DOI: 10. 7759/cureus. 40259
  65. Kosten T, Domingo C, Orson F, Kinsey B. Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol. 2014;77(2):368–374. DOI: 10. 1111/bcp. 12115
  66. Lee JC, Eubanks LM, Zhou B, Janda KD. Development of an effective monoclonal antibody against heroin and its metabolites reveals therapies have mistargeted 6-monoacetylmorphine and morphine over heroin. ACS Cent Sci. 2022;8(10):1464–1470. doi: 10. 1021/acscentsci. 2c00977
  67. Eubanks LM, Pholcharee T, Oyen D, et al. An engineered human-antibody fragment with fentanyl pan-specificity that reverses carfentanil-induced respiratory depression. bioRxiv. 2023;2023:547721. doi: 10. 1101/2023. 07. 04. 547721
  68. Orson FM, Kinsey BM, Singh RA, et al. The future of vaccines in the management of addictive disorders. Curr Psychiatry Rep. 2007;9(5):381–387. DOI: 10. 1007/s11920-007-0049-z

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 84654 от 01.02.2023 г

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies